Last10K.com

Biorestorative Therapies, Inc. (BRTX) SEC Filing 10-Q Quarterly report for the period ending Monday, September 30, 2019

Biorestorative Therapies, Inc.

HISTORY TOOLS
CIK: 1505497 Ticker: BRTX
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2019
Nov. 11, 2019
Document And Entity Information [Abstract]  
Entity Registrant NameBioRestorative Therapies, Inc. 
Entity Central Index Key0001505497 
Document Type10-Q 
Document Period End DateSep. 30, 2019 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Business Flagtrue 
Entity Emerging Growth Companytrue 
Entity Ex Transition Periodfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 30,761,527
Document Fiscal Period FocusQ3 
Document Fiscal Year Focus2019 

View differences made from one quarter to another to evaluate Biorestorative Therapies, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biorestorative Therapies, Inc..

Continue

Assess how Biorestorative Therapies, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Biorestorative Therapies, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Changes In Stockholders' Deficiency (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Details Narrative)
Accrued Expenses And Other Current Liabilities (Tables)
Accrued Expenses And Other Current Liabilities - Schedule Of Accrued Expenses And Other Current Liabilities (Details)
Business Organization And Nature Of Operations
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Derivative Liabilities
Derivative Liabilities (Details Narrative)
Derivative Liabilities (Tables)
Derivative Liabilities - Summary Of Changes In Fair Value Of Level 3 Derivative Liabilities (Details)
Derivative Liabilities - Summary Of Derivative Liabilities Fair Value Assumption (Details)
Going Concern And Management's Plans
Going Concern And Management's Plans (Details Narrative)
Notes Payable
Notes Payable (Details Narrative)
Notes Payable (Tables)
Notes Payable - Schedule Of Notes Payable Activity (Details)
Notes Payable - Schedule Of Notes Payable Activity (Details) (Parenthetical)
Stockholders' Deficiency
Stockholders' Deficiency (Details Narrative)
Stockholders' Deficiency (Tables)
Stockholders' Deficiency - Schedule Of Stock Option Activity (Details)
Stockholders' Deficiency - Schedule Of Stock Option By Exercise Price (Details)
Stockholders' Deficiency - Schedule Of Stock Option Expense (Details)
Stockholders' Deficiency - Schedule Of Stock Option Granted Assumptions (Details)
Stockholders' Deficiency - Schedule Of Stock Warrants (Details)
Stockholders' Deficiency - Schedule Of Warrant Activity (Details)
Stockholders' Deficiency - Schedule Of Warrants Granted Assumptions (Details)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Schedule Of Weighted Average Dilutive Common Shares (Details)
Summary Of Significant Accounting Policies - Schedule Of Weighted Average Dilutive Common Shares (Details) (Parenthetical)

Material Contracts, Statements, Certifications & more

Biorestorative Therapies, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 3.1: Articles Of Incorporation
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32: Section 1350 Certification
Ticker: BRTX
CIK: 1505497
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-19-017053
Submitted to the SEC: Wed Nov 13 2019 4:59:45 PM EST
Accepted by the SEC: Wed Nov 13 2019
Period: Monday, September 30, 2019
Industry: Health And Allied

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/brtx/0001493152-19-017053.htm